Dyne Therapeutics (NASDAQ:DYN) Insider Douglas Kerr Sells 1,290 Shares of Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) insider Douglas Kerr sold 1,290 shares of Dyne Therapeutics stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $18.88, for a total value of $24,355.20. Following the completion of the sale, the insider directly owned 162,564 shares in the company, valued at $3,069,208.32. This trade represents a 0.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Douglas Kerr also recently made the following trade(s):

• On Friday, September 4th, Douglas Kerr sold 3,745 shares of Dyne Therapeutics stock. The shares were sold at an average price of $24.35, for a total value of $91,190.75.

Dyne Therapeutics Stock Performance

NASDAQ DYN opened at $20.31 on Wednesday. The stock has a market capitalization of $3.79 billion, a PE ratio of -6.10 and a beta of 1.08. The business has a 50 day simple moving average of $24.82 and a two-hundred day simple moving average of $20.49. The company has a debt-to-equity ratio of 0.28, a current ratio of 12.02 and a quick ratio of 12.02. Dyne Therapeutics, Inc. has a 1-year low of $11.92 and a 1-year high of $27.31.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33). On average, research analysts predict that Dyne Therapeutics, Inc. will post -3.47 EPS for the current fiscal year.

Institutional Trading of Dyne Therapeutics

A number of institutional investors have recently bought and sold shares of DYN. Handelsbanken Fonder AB purchased a new position in shares of Dyne Therapeutics during the 2nd quarter worth about $1,182,000. Fisher Asset Management LLC purchased a new stake in Dyne Therapeutics in the 4th quarter worth about $4,891,000. Royal Bank of Canada raised its position in Dyne Therapeutics by 267.6% in the 1st quarter. Royal Bank of Canada now owns 68,188 shares of the company’s stock worth $1,236,000 after purchasing an additional 49,641 shares during the period. Cibc World Market Inc. bought a new stake in Dyne Therapeutics in the fourth quarter worth about $1,345,000. Finally, Clearbridge Investments LLC bought a new stake in Dyne Therapeutics in the fourth quarter worth about $7,976,000. 96.68% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

DYN has been the topic of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Dyne Therapeutics in a research note on Monday, August 17th. Sanford C. Bernstein lifted their price objective on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research note on Wednesday, May 13th. Wall Street Zen downgraded shares of Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Friday, July 17th. Finally, TD Cowen started coverage on shares of Dyne Therapeutics in a report on Friday, June 26th. They issued a “buy” rating for the company. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Dyne Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $34.17.

Key Headlines Impacting Dyne Therapeutics

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: Dyne announced that it will present additional six- and 12-month data from the Phase 1/2 ACHIEVE trial of z-basivarsen (DYNE-101) at the World Muscle Society and AANEM meetings beginning September 29-30. The data will include comparisons with a matched natural-history cohort and updated safety results. Dyne ACHIEVE trial data announcement
• Positive Sentiment: The ACHIEVE registrational expansion cohort is fully enrolled, and Dyne expects topline results in the first quarter of 2027. DYNE-101 also has FDA Breakthrough Therapy, Orphan Drug and Fast Track designations, supporting the potential for an expedited development path. Quiver Quantitative ACHIEVE summary
• Neutral Sentiment: Call-option activity surged, with traders purchasing approximately 20,532 calls versus average daily volume of about 464. This may reflect speculative expectations for a rebound or upcoming data, but options activity does not confirm a fundamental improvement.
• Negative Sentiment: Reports said DYN fell heavily after a rival DM1 drug failed in Phase 3. Investors appear concerned that the setback could signal clinical or commercial risks for the DM1 field, even though Dyne’s own upcoming one-year data have not yet been released. RTT News report on rival DM1 failure
• Negative Sentiment: Several executives, including CEO John Cox, reported stock sales. The transactions were made to cover tax withholding on vested equity awards and were relatively small compared with their remaining holdings, limiting their direct significance, but the cluster of sales may add to cautious sentiment.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.